On January 10, 2022, Black Diamond Therapeutics, Inc. announced that the US Food and Drug Administration had allowed its Investigational New Drug application for BDTX-1535. The company expects to initiate the Phase 1 study of BDTX-1535 in the first quarter of 2022 and expects to provide a clinical update in the second half of 2023.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.235 USD | +3.57% |
|
+23.15% | +119.57% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+119.57% | 339M | |
+20.31% | 127B | |
+24.63% | 117B | |
+25.44% | 27.67B | |
-17.71% | 20.33B | |
-15.17% | 16.79B | |
-14.89% | 15.63B | |
+12.47% | 14.84B | |
-47.10% | 14.65B | |
+56.65% | 14.43B |
- Stock Market
- Equities
- BDTX Stock
- News Black Diamond Therapeutics, Inc.
- Black Diamond Therapeutics, Inc. Announces US Food and Drug Administration Allows its Investigational New Drug Application for BDTX-1535